Expression Of Key Immunology Drug Targets In CHDR Human Inflammatory Challenge Models

Advances in immunology drug development increasingly center on precise modulation of cytokines, receptors, and intracellular signalling pathways that drive inflammation. Human challenge models provide a controlled way to activate these pathways in vivo, creating a critical bridge between preclinical findings and early clinical decision making.

Integrated transcriptomic and proteomic data reveal how widely used challenge approaches capture distinct aspects of immune activation, from innate responses driven by lipopolysaccharide to adaptive mechanisms engaged by antigen-based models and psoriasis-like inflammation triggered by imiquimod. These complementary profiles enable a deeper understanding of target expression and pathway engagement across key therapeutic areas.

By aligning experimental models with the most relevant drug targets, development teams can generate clearer pharmacodynamic signals, refine dose selection, and de-risk early programs. Explore how these translational insights can strengthen your next phase of immunology research.